Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients
Stopped early · Phase 1/Phase 2
Conditions studied: Metastatic Colorectal Cancer
In brief
This is a Phase 1b/2a study investigating the safety and efficacy of Sym004, an investigational medicinal product (IMP), in combination with FOLFIRI (chemotherapy) when administered every second week (Q2W).
Key facts
- Study ID
- NCT02568046
- Run by
- Symphogen A/S
- People needed
- 10
- Starts
- 2016-03-15
- Expected to finish
- 2018-05-05
- Last updated by the study team
- 2019-03-26
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UCLA School of Medicine — Los Angeles, California, United States
- Sharp Memorial Hosptal — San Diego, California, United States
- Georgetown University Medical Center — Washington D.C., District of Columbia, United States
- University Cancer & Blood Center, LLC — Athens, Georgia, United States
- University of Michigan Health System — Ann Arbor, Michigan, United States
- Hospital del Mar — Barcelona, Spain
- Hospital Universitari Vall d'Hebron — Barcelona, Spain
- Hospital Universitario Madrid Sanchinarro — Madrid, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.